Status:

TERMINATED

Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5

Lead Sponsor:

Shire

Conditions:

Kidney Diseases

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The main aim of this research study is to see if giving Fosrenol®, a chewable tablet, to patients on haemodialysis works as well as other treatments currently used to lower blood phosphorus levels.

Eligibility Criteria

Inclusion

  • Male or female subjects greater than or equal to 18 years of age receiving a stable regimen of haemodialysis for chronic kidney disease (CKD) Stage 5 (defined as haemodialysis two or three times per week for at least two months prior to screening).
  • Females of child bearing potential (FOCP) must be non-pregnant, non-lactating, have a negative serum beta human chorionic gonadotropin (HCG) test, and agree to comply with any applicable contraceptive requirements of the protocol.
  • Subjects on a stable phosphate binder dose (defined as no change in medication or dosage for at least the one month prior to screening) with a serum phosphorus level between greater than 1.78 and less than or equal to 2.43 mmol/L (5.5 and 7.5 mg/dL).

Exclusion

  • Subjects with a corrected serum calcium level less than 2.1 mmol/L (8.5 mg/dL).
  • Subjects with an intact parathyroid hormone (iPTH) level greater than 500 pg/mL, or a history of previous parathyroidectomy within 12 months of screening.
  • Subjects with any significant bowel obstruction, active inflammatory bowel disease, gastrointestinal (GI) motility disorders, abnormal or irregular bowel motion, or a history of major GI surgery within the last 6 months will be excluded.
  • Subjects receiving aluminium, magnesium, or combination therapy other than sevelamer hydrogen chloride (HCl) and calcium as a phosphate binder at the time of screening will be excluded.

Key Trial Info

Start Date :

May 22 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 10 2007

Estimated Enrollment :

68 Patients enrolled

Trial Details

Trial ID

NCT00452478

Start Date

May 22 2007

End Date

December 10 2007

Last Update

May 25 2021

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

Landeskrankenhaus Feldkirch, Abteilung fur Nephrologie und dialyse

Feldkirch Tisis, Austria, A-6807

2

Krankenhaus Elisabethinen/Dialysestation

Linz, Austria, A-4010

3

Ziekenhuis Zuid Oost Limburg

Genk, Belgium, 3600

4

Frederica Sygehus

Fredericia, Denmark, 7000